The global market for Immune-mediated Necrotizing Myopathy Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immune-mediated Necrotizing Myopathy Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immune-mediated Necrotizing Myopathy Treatment by region & country, by Type, and by Application.

The Immune-mediated Necrotizing Myopathy Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune-mediated Necrotizing Myopathy Treatment.

Market Segmentation

Scope of Immune-mediated Necrotizing Myopathy Treatment - Market Report

Report Metric	Details
Report Name	Immune-mediated Necrotizing Myopathy Treatment - Market
CAGR	5%
Segment by Type:	Steroids Immunosuppressant Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immune-mediated Necrotizing Myopathy Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Immune-mediated Necrotizing Myopathy Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Immune-mediated Necrotizing Myopathy Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Immune-mediated Necrotizing Myopathy Treatment - Market report?

Ans: The main players in the Immune-mediated Necrotizing Myopathy Treatment - Market are GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG

What are the Application segmentation covered in the Immune-mediated Necrotizing Myopathy Treatment - Market report?

Ans: The Applications covered in the Immune-mediated Necrotizing Myopathy Treatment - Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Immune-mediated Necrotizing Myopathy Treatment - Market report?

Ans: The Types covered in the Immune-mediated Necrotizing Myopathy Treatment - Market report are Steroids, Immunosuppressant, Others

1 Market Overview

1.1 Immune-mediated Necrotizing Myopathy Treatment Product Introduction

1.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Forecast

1.3 Immune-mediated Necrotizing Myopathy Treatment Market Trends & Drivers

1.3.1 Immune-mediated Necrotizing Myopathy Treatment Industry Trends

1.3.2 Immune-mediated Necrotizing Myopathy Treatment Market Drivers & Opportunity

1.3.3 Immune-mediated Necrotizing Myopathy Treatment Market Challenges

1.3.4 Immune-mediated Necrotizing Myopathy Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Immune-mediated Necrotizing Myopathy Treatment Players Revenue Ranking (2023)

2.2 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2019-2024)

2.3 Key Companies Immune-mediated Necrotizing Myopathy Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Immune-mediated Necrotizing Myopathy Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Immune-mediated Necrotizing Myopathy Treatment

2.6 Immune-mediated Necrotizing Myopathy Treatment Market Competitive Analysis

2.6.1 Immune-mediated Necrotizing Myopathy Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Immune-mediated Necrotizing Myopathy Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune-mediated Necrotizing Myopathy Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Steroids

3.1.2 Immunosuppressant

3.1.3 Others

3.2 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type

3.2.1 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Others

4.2 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application

4.2.1 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region

5.1.1 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2019-2024)

5.1.3 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2025-2030)

5.1.4 Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

5.2.2 North America Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

5.3.2 Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

5.5.2 South America Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value

6.3 United States

6.3.1 United States Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.3.2 United States Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.4.2 Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.5.2 China Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.6.2 Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.7.2 South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019-2030

6.9.2 India Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 GlaxoSmithKline plc

7.1.1 GlaxoSmithKline plc Profile

7.1.2 GlaxoSmithKline plc Main Business

7.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.1.4 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 GlaxoSmithKline plc Recent Developments

7.2 Dr. Reddy's Laboratories

7.2.1 Dr. Reddy's Laboratories Profile

7.2.2 Dr. Reddy's Laboratories Main Business

7.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.2.4 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Dr. Reddy's Laboratories Recent Developments

7.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)

7.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Profile

7.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Main Business

7.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Hetero Drugs Limited Recent Developments

7.4 Hetero Drugs Limited

7.4.1 Hetero Drugs Limited Profile

7.4.2 Hetero Drugs Limited Main Business

7.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.4.4 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Hetero Drugs Limited Recent Developments

7.5 AbbVie Inc.

7.5.1 AbbVie Inc. Profile

7.5.2 AbbVie Inc. Main Business

7.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.5.4 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 AbbVie Inc. Recent Developments

7.6 Teva Pharmaceutical Industries

7.6.1 Teva Pharmaceutical Industries Profile

7.6.2 Teva Pharmaceutical Industries Main Business

7.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.6.4 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Teva Pharmaceutical Industries Recent Developments

7.7 Novartis AG

7.7.1 Novartis AG Profile

7.7.2 Novartis AG Main Business

7.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

7.7.4 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Novartis AG Recent Developments

8 Industry Chain Analysis

8.1 Immune-mediated Necrotizing Myopathy Treatment Industrial Chain

8.2 Immune-mediated Necrotizing Myopathy Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Immune-mediated Necrotizing Myopathy Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Immune-mediated Necrotizing Myopathy Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

GlaxoSmithKline PLC

Dr. Reddy’s Laboratories

Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)

Hetero Drugs Limited

AbbVie

Teva Pharmaceutical Industries

Novartis

List of Tables

Table 1. Immune-mediated Necrotizing Myopathy Treatment Market Trends

Table 2. Immune-mediated Necrotizing Myopathy Treatment Market Drivers & Opportunity

Table 3. Immune-mediated Necrotizing Myopathy Treatment Market Challenges

Table 4. Immune-mediated Necrotizing Myopathy Treatment Market Restraints

Table 5. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Immune-mediated Necrotizing Myopathy Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Immune-mediated Necrotizing Myopathy Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Immune-mediated Necrotizing Myopathy Treatment

Table 10. Global Immune-mediated Necrotizing Myopathy Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune-mediated Necrotizing Myopathy Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Immune-mediated Necrotizing Myopathy Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Immune-mediated Necrotizing Myopathy Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Immune-mediated Necrotizing Myopathy Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Immune-mediated Necrotizing Myopathy Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. GlaxoSmithKline plc Basic Information List

Table 32. GlaxoSmithKline plc Description and Business Overview

Table 33. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of GlaxoSmithKline plc (2019-2024)

Table 35. GlaxoSmithKline plc Recent Developments

Table 36. Dr. Reddy's Laboratories Basic Information List

Table 37. Dr. Reddy's Laboratories Description and Business Overview

Table 38. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of Dr. Reddy's Laboratories (2019-2024)

Table 40. Dr. Reddy's Laboratories Recent Developments

Table 41. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Basic Information List

Table 42. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Description and Business Overview

Table 43. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) (2019-2024)

Table 45. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Developments

Table 46. Hetero Drugs Limited Basic Information List

Table 47. Hetero Drugs Limited Description and Business Overview

Table 48. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of Hetero Drugs Limited (2019-2024)

Table 50. Hetero Drugs Limited Recent Developments

Table 51. AbbVie Inc. Basic Information List

Table 52. AbbVie Inc. Description and Business Overview

Table 53. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of AbbVie Inc. (2019-2024)

Table 55. AbbVie Inc. Recent Developments

Table 56. Teva Pharmaceutical Industries Basic Information List

Table 57. Teva Pharmaceutical Industries Description and Business Overview

Table 58. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of Teva Pharmaceutical Industries (2019-2024)

Table 60. Teva Pharmaceutical Industries Recent Developments

Table 61. Novartis AG Basic Information List

Table 62. Novartis AG Description and Business Overview

Table 63. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Immune-mediated Necrotizing Myopathy Treatment Business of Novartis AG (2019-2024)

Table 65. Novartis AG Recent Developments

Table 66. Key Raw Materials Lists

Table 67. Raw Materials Key Suppliers Lists

Table 68. Immune-mediated Necrotizing Myopathy Treatment Downstream Customers

Table 69. Immune-mediated Necrotizing Myopathy Treatment Distributors List

Table 70. Research Programs/Design for This Report

Table 71. Key Data Information from Secondary Sources

Table 72. Key Data Information from Primary Sources

Table 73. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Immune-mediated Necrotizing Myopathy Treatment Product Picture

Figure 2. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Immune-mediated Necrotizing Myopathy Treatment Report Years Considered

Figure 5. Global Immune-mediated Necrotizing Myopathy Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Immune-mediated Necrotizing Myopathy Treatment Revenue in 2023

Figure 7. Immune-mediated Necrotizing Myopathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Steroids Picture

Figure 9. Immunosuppressant Picture

Figure 10. Others Picture

Figure 11. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Hospital

Figure 14. Product Picture of Clinic

Figure 15. Product Picture of Others

Figure 16. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Immune-mediated Necrotizing Myopathy Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 19. North America Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

Figure 24. South America Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 25. South America Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions Immune-mediated Necrotizing Myopathy Treatment Sales Value (%), (2019-2030)

Figure 29. United States Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 31. United States Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 35. China Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 36. China Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 37. China Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 47. India Immune-mediated Necrotizing Myopathy Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 48. India Immune-mediated Necrotizing Myopathy Treatment Sales Value by Type (%), 2023 VS 2030

Figure 49. India Immune-mediated Necrotizing Myopathy Treatment Sales Value by Application (%), 2023 VS 2030

Figure 50. Immune-mediated Necrotizing Myopathy Treatment Industrial Chain

Figure 51. Immune-mediated Necrotizing Myopathy Treatment Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions